Generalized epileptic seizures; partial (focal) seizures with simple and complex symptoms; convulsive syndrome in organic brain diseases; behavior disorders caused by epilepsy; febrile seizures in children.
Encorat 500 mg. Storage
active substances: sodium valproate and valproic acid;
1 tablet contains 133.5 mg of sodium valproate and 58 mg of valproic acid, which corresponds to 200 mg of sodium valproate;
1 tablet contains 200 mg of sodium valproate and 87 mg of valproic acid, which corresponds to 300 mg of sodium valproate;
1 tablet contains 333 mg of sodium valproate and 145 mg of valproic acid, which corresponds to 500 mg of sodium valproate;
Encorat 500 mg. Excipients: hypromellose, corn starch, colloidal anhydrous silica, talc, magnesium stearate, acrylate copolymer, titanium dioxide (E 171), yellow FCF (E 110), polyethylene glycol 6000.
Encorat 500 mg. Dosage form
Basic physical and chemical properties:
round, biconvex, orange-coated tablets, smooth on both sides (200 mg, 300 mg);
capsule-shaped tablets, coated with orange, smooth on both sides (500 mg).
Antiepileptic drugs. ATX code N03A G01.
In animal pharmacology, sodium valproate has been shown to have anticonvulsant properties in various models of experimental epilepsy (with generalized and focal seizures).
Similarly, studies have shown that sodium valproate has an antiepileptic effect in various forms of epilepsy in humans. Presumably, this action is based on GABA-ergic (gamma-aminobutyric acid-mediated) activity, which prevents or limits the diffusion of discharges.
Some in vitro studies have shown that sodium valproate can stimulate HIV-1 replication, but this effect is weak and has not been reproducible in most studies. The clinical consequences of this effect in patients infected with HIV-1 are unknown. When using valproate sodium in patients infected with HIV-1, this information should be taken into account for the correct interpretation of the results of viral load analysis.
Absorption. After oral administration of the drug Encorat Chrono, its bioavailability in blood plasma approaches 100%.
In blood plasma, the drug is in the form of valproic acid. Absorption of the drug Encorat Chrono, tablets, coated, prolonged action, in the gastrointestinal tract begins immediately and has a uniform and prolonged nature. This achieves the absence of peak plasma concentrations of the active substance and better maintenance of therapeutic concentrations of valproic acid over time.